{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:57:05Z","timestamp":1791669425304,"version":"4.3.4"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scientific Publications Services"},{"name":"Research Medical Library"},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glioblastoma (GBM), the most aggressive primary brain tumor, has a dismal prognosis. Despite our growing knowledge of genomic and epigenomic alterations in GBM, standard therapies and outcomes have not changed significantly in the past two decades. There is therefore an urgent unmet need to develop novel therapies for GBM. The inter- and intratumoral heterogeneity of GBM, inadequate drug concentrations in the tumor owing to the blood\u2013brain barrier, redundant signaling pathways contributing to resistance to conventional therapies, and an immunosuppressive tumor microenvironment, have all hindered the development of novel therapies for GBM. Given the high frequency of DNA damage pathway alterations in GBM, researchers have focused their efforts on pharmacologically targeting key enzymes, including poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase, ataxia telangiectasia-mutated, and ataxia telangiectasia and Rad3-related. The mainstays of GBM treatment, ionizing radiation and alkylating chemotherapy, generate DNA damage that is repaired through the upregulation and activation of DNA damage response (DDR) enzymes. Therefore, the use of PARP and other DDR inhibitors to render GBM cells more vulnerable to conventional treatments is an area of intense investigation. In this review, we highlight the growing body of data behind DDR inhibitors in GBM, with a focus on putative predictive biomarkers of response. We also discuss the challenges involved in the successful development of DDR inhibitors for GBM, including the intracranial location and predicted overlapping toxicities of DDR agents with current standards of care, and propose promising strategies to overcome these hurdles.<\/jats:p>","DOI":"10.1093\/noajnl\/vdab015","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T02:34:25Z","timestamp":1612578865000},"source":"Crossref","is-referenced-by-count":34,"title":["The promise of DNA damage response inhibitors for the treatment of glioblastoma"],"prefix":"10.1093","volume":"3","author":[{"given":"Nazanin K","family":"Majd","sequence":"first","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy","family":"Koul","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerakumar","family":"Balasubramaniyan","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabbir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katilin S","family":"Gandy","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W K Alfred","family":"Yung","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"issue":"10","key":"2021031215311187000_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2021031215311187000_CIT0002","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/neuonc\/now182","article-title":"Tumor treating fields: a novel treatment modality and its use in brain tumors","volume":"18","author":"Hottinger","year":"2016","journal-title":"Neuro Oncol."},{"issue":"7216","key":"2021031215311187000_CIT0003","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research N.","year":"2008","journal-title":"Nature"},{"issue":"2","key":"2021031215311187000_CIT0004","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"6","key":"2021031215311187000_CIT0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2019.11.008","article-title":"Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell."},{"issue":"6","key":"2021031215311187000_CIT0006","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP Inhibitor) in Glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2021031215311187000_CIT0007","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.0830918100","article-title":"Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses","volume":"100","author":"Rothkamm","year":"2003","journal-title":"Proc Natl Acad Sci USA."},{"key":"2021031215311187000_CIT0008","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.dnarep.2014.03.021","article-title":"Protein ADP-ribosylation and the cellular response to DNA strand breaks","volume":"19","author":"Caldecott","year":"2014","journal-title":"DNA Repair (Amst)."},{"issue":"15","key":"2021031215311187000_CIT0009","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1091\/mbc.e16-01-0032","article-title":"Hyperactivation of ATM upon DNA-PKcs inhibition modulates p53 dynamics and cell fate in response to DNA damage","volume":"27","author":"Finzel","year":"2016","journal-title":"Mol Biol Cell."},{"issue":"10","key":"2021031215311187000_CIT0010","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2021031215311187000_CIT0011","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molcel.2006.04.023","article-title":"ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts","volume":"22","author":"Yoshioka","year":"2006","journal-title":"Mol Cell."},{"issue":"3","key":"2021031215311187000_CIT0012","first-page":"478","article-title":"DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system","volume":"66","author":"Caporali","year":"2004","journal-title":"Mol Pharmacol."},{"issue":"8","key":"2021031215311187000_CIT0013","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","article-title":"Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021031215311187000_CIT0014","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.2011.285","article-title":"Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours","volume":"105","author":"Tawbi","year":"2011","journal-title":"Br J Cancer."},{"issue":"2-3","key":"2021031215311187000_CIT0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pbiomolbio.2014.12.003","article-title":"The DNA-dependent protein kinase: a multifunctional protein kinase with roles in DNA double strand break repair and mitosis","volume":"117","author":"Jette","year":"2015","journal-title":"Prog Biophys Mol Biol."},{"issue":"38","key":"2021031215311187000_CIT0016","doi-asserted-by":"crossref","first-page":"27784","DOI":"10.1074\/jbc.M603047200","article-title":"Interplay between Ku, Artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends","volume":"281","author":"Drouet","year":"2006","journal-title":"J Biol Chem."},{"issue":"5","key":"2021031215311187000_CIT0017","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1159\/000495899","article-title":"Sodium fluoride arrests renal G2\/M phase cell-cycle progression by activating ATM-Chk2-P53\/Cdc25C signaling pathway in mice","volume":"51","author":"Luo","year":"2018","journal-title":"Cell Physiol Biochem."},{"issue":"13","key":"2021031215311187000_CIT0018","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1128\/MCB.25.13.5363-5379.2005","article-title":"ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1","volume":"25","author":"You","year":"2005","journal-title":"Mol Cell Biol."},{"issue":"5625","key":"2021031215311187000_CIT0019","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science."},{"issue":"9","key":"2021031215311187000_CIT0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dnarep.2009.04.012","article-title":"Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response","volume":"8","author":"Stracker","year":"2009","journal-title":"DNA Repair (amst)."},{"issue":"7267","key":"2021031215311187000_CIT0021","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature."},{"issue":"4","key":"2021031215311187000_CIT0022","doi-asserted-by":"crossref","first-page":"157","DOI":"10.36401\/JIPO-20-20","article-title":"The promise of poly(ADP-Ribose) polymerase (PARP) inhibitors in Gliomas","volume":"3","author":"Majd","year":"2020","journal-title":"Journal of Immunotherapy and Precision Oncology"},{"issue":"23","key":"2021031215311187000_CIT0023","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1158\/1078-0432.CCR-16-0247","article-title":"Biomarkers of response and resistance to DNA repair targeted therapies","volume":"22","author":"Stover","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2021031215311187000_CIT0024","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/2159-8290.CD-14-0358","article-title":"Beyond DNA repair: DNA-PK function in cancer","volume":"4","author":"Goodwin","year":"2014","journal-title":"Cancer Discov."},{"issue":"8","key":"2021031215311187000_CIT0025","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","article-title":"Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches","volume":"30","author":"Dietlein","year":"2014","journal-title":"Trends Genet."},{"issue":"189","key":"2021031215311187000_CIT0026","doi-asserted-by":"crossref","first-page":"189ra178","DOI":"10.1126\/scitranslmed.3005814","article-title":"Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors","volume":"5","author":"Riabinska","year":"2013","journal-title":"Sci Transl Med"},{"issue":"34","key":"2021031215311187000_CIT0027","doi-asserted-by":"crossref","first-page":"55555","DOI":"10.18632\/oncotarget.10864","article-title":"Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling","volume":"7","author":"Lan","year":"2016","journal-title":"Oncotarget."},{"issue":"3","key":"2021031215311187000_CIT0028","doi-asserted-by":"crossref","first-page":"e98096","DOI":"10.1172\/jci.insight.98096","article-title":"Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"2021031215311187000_CIT0029","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic Xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"2021031215311187000_CIT0030","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1541-7786.MCR-19-0362","article-title":"Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814","volume":"17","author":"Sun","year":"2019","journal-title":"Mol Cancer Res."},{"issue":"1","key":"2021031215311187000_CIT0031","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell."},{"key":"2021031215311187000_CIT0032","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag Res."},{"issue":"9","key":"2021031215311187000_CIT0033","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro Oncol."},{"issue":"4","key":"2021031215311187000_CIT0034","first-page":"1657","article-title":"Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme","volume":"33","author":"Lassen","year":"2013","journal-title":"Anticancer Res."},{"issue":"19","key":"2021031215311187000_CIT0035","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2021031215311187000_CIT0036","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1158\/1535-7163.MCT-13-0136","article-title":"Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide","volume":"12","author":"Eich","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"2021031215311187000_CIT0037","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)80086-0","article-title":"Atm-deficient mice: a paradigm of ataxia telangiectasia","volume":"86","author":"Barlow","year":"1996","journal-title":"Cell."},{"issue":"33","key":"2021031215311187000_CIT0038","doi-asserted-by":"crossref","first-page":"12091","DOI":"10.1073\/pnas.1400230111","article-title":"UBR5-mediated ubiquitination of ATMIN is required for ionizing radiation-induced ATM signaling and function","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2021031215311187000_CIT0039","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","article-title":"ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation","volume":"19","author":"Biddlestone-Thorpe","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2021031215311187000_CIT0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell Cycle."},{"issue":"6","key":"2021031215311187000_CIT0041","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/ijc.29121","article-title":"Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019","volume":"136","author":"Vecchio","year":"2015","journal-title":"Int J Cancer."},{"issue":"8","key":"2021031215311187000_CIT0042","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","article-title":"Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice","volume":"17","author":"Karlin","year":"2018","journal-title":"Mol Cancer Ther."},{"issue":"6","key":"2021031215311187000_CIT0043","doi-asserted-by":"crossref","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"issue":"1","key":"2021031215311187000_CIT0044","doi-asserted-by":"crossref","first-page":"e55665","DOI":"10.1371\/journal.pone.0055665","article-title":"Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage","volume":"8","author":"Knizhnik","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2021031215311187000_CIT0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","article-title":"Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-\u03baB","volume":"79","author":"Aasland","year":"2019","journal-title":"Cancer Res."},{"issue":"17","key":"2021031215311187000_CIT0046","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"issue":"20","key":"2021031215311187000_CIT0047","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/0008-5472.CAN-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res."},{"key":"2021031215311187000_CIT0048","first-page":"3007-3007","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors","volume":"37","author":"Bono","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021031215311187000_CIT0049","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell."},{"issue":"6","key":"2021031215311187000_CIT0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.19240","article-title":"Enhancing CHK1 inhibitor lethality in glioblastoma","volume":"13","author":"Tang","year":"2012","journal-title":"Cancer Biol Ther."},{"issue":"3","key":"2021031215311187000_CIT0051","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.109.154997","article-title":"Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]","volume":"331","author":"Jobson","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"2021031215311187000_CIT0052","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccr.2010.08.011","article-title":"In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma","volume":"18","author":"Mir","year":"2010","journal-title":"Cancer Cell."},{"issue":"1","key":"2021031215311187000_CIT0053","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/neuonc\/nox128","article-title":"Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma","volume":"20","author":"Wu","year":"2018","journal-title":"Neuro Oncol."},{"issue":"8","key":"2021031215311187000_CIT0054","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-14-2588","article-title":"The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood\u2013brain barrier in glioblastoma","volume":"21","author":"Pokorny","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2021031215311187000_CIT0055","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 Trial of AZD1775 in first-recurrence glioblastoma patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin Cancer Res."},{"key":"2021031215311187000_CIT0056","doi-asserted-by":"crossref","first-page":"2005-2005","DOI":"10.1200\/JCO.2017.35.15_suppl.2005","article-title":"Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM","volume":"35","author":"Alexander","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021031215311187000_CIT0057","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"issue":"2","key":"2021031215311187000_CIT0058","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1634\/theoncologist.2017-0501","article-title":"Phase II study of bevacizumab and vorinostat for patients with recurrent world health organization grade 4 malignant glioma","volume":"23","author":"Ghiaseddin","year":"2018","journal-title":"Oncologist."},{"issue":"354","key":"2021031215311187000_CIT0059","doi-asserted-by":"crossref","first-page":"354re353","DOI":"10.1126\/scitranslmed.aaf6853","article-title":"Origin of the U87MG glioma cell line: good news and bad news","volume":"8","author":"Allen","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"2021031215311187000_CIT0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00401-017-1671-4","article-title":"Glioma: experimental models and reality","volume":"133","author":"Lenting","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2021031215311187000_CIT0061","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng.3711","article-title":"Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation","volume":"49","author":"Shingu","year":"2017","journal-title":"Nat Genet."},{"key":"2021031215311187000_CIT0062","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08711","article-title":"Inactivation of the ATMIN\/ATM pathway protects against glioblastoma formation","volume":"5","author":"Blake","year":"2016","journal-title":"Elife"},{"issue":"9","key":"2021031215311187000_CIT0063","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","article-title":"The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)","volume":"61","author":"Pike","year":"2018","journal-title":"J Med Chem."},{"issue":"375","key":"2021031215311187000_CIT0064","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"issue":"17","key":"2021031215311187000_CIT0065","doi-asserted-by":"crossref","first-page":"eaaz3221","DOI":"10.1126\/sciadv.aaz3221","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv"},{"issue":"7","key":"2021031215311187000_CIT0066","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-Mediated DNA Repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"issue":"12","key":"2021031215311187000_CIT0067","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol."},{"issue":"12","key":"2021031215311187000_CIT0068","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-15-0553","article-title":"Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system","volume":"14","author":"Parrish","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"2021031215311187000_CIT0069","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"2021031215311187000_CIT0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","article-title":"Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor","volume":"22","author":"Xiong","year":"2020","journal-title":"Neoplasia."},{"issue":"9","key":"2021031215311187000_CIT0071","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2021031215311187000_CIT0072","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","article-title":"Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in Glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"2021031215311187000_CIT0073","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00401-018-1810-6","article-title":"The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033","volume":"135","author":"Bady","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"22","key":"2021031215311187000_CIT0074","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.1002\/cam4.3447","article-title":"Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes","volume":"9","author":"Kessler","year":"2020","journal-title":"Cancer Med."},{"issue":"18","key":"2021031215311187000_CIT0075","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2005.07.144","article-title":"Use of magnetic resonance imaging to assess blood-brain\/blood-glioma barrier opening during conformal radiotherapy","volume":"23","author":"Cao","year":"2005","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021031215311187000_CIT0076","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/1078-0432.CCR-06-2489","article-title":"Targeted therapy for brain metastases: improving the therapeutic ratio","volume":"13","author":"Patel","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021031215311187000_CIT0077","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1148\/radiol.10092343","article-title":"Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media","volume":"257","author":"Lemasson","year":"2010","journal-title":"Radiology."},{"issue":"13","key":"2021031215311187000_CIT0078","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/14656566.2019.1621840","article-title":"Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma","volume":"20","author":"Majd","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2021031215311187000_CIT0079","doi-asserted-by":"crossref","first-page":"2006-2006","DOI":"10.1200\/JCO.2018.36.15_suppl.2006","article-title":"Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients","volume":"36","author":"Reardon","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021031215311187000_CIT0080","first-page":"iii21-iii21","article-title":"OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkmate 143","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro Oncol"},{"key":"2021031215311187000_CIT0081","author":"Bristol-Myers Squibb."},{"issue":"4","key":"2021031215311187000_CIT0082","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2020","journal-title":"Neuro Oncol."},{"issue":"13","key":"2021031215311187000_CIT0083","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP inhibitors: extending benefit beyond BRCA-Mutant cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2021031215311187000_CIT0084","doi-asserted-by":"crossref","first-page":"4719194","DOI":"10.1155\/2017\/4719194","article-title":"Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy","volume":"2017","author":"Viale","year":"2017","journal-title":"Biomed Res Int."},{"issue":"1","key":"2021031215311187000_CIT0085","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent innate immune signaling by S-Phase-Specific DNA damage in breast cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2021031215311187000_CIT0086","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"2021031215311187000_CIT0087","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med."},{"issue":"1","key":"2021031215311187000_CIT0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021031215311187000_CIT0089","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021031215311187000_CIT0090","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","article-title":"Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy","volume":"6","author":"Johanns","year":"2016","journal-title":"Cancer Discov."},{"issue":"14","key":"2021031215311187000_CIT0091","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2021031215311187000_CIT0092","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_238473","article-title":"The DNA damaging revolution: PARP inhibitors and beyond","volume":"39","author":"Yap","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"7804","key":"2021031215311187000_CIT0093","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature."},{"key":"2021031215311187000_CIT0094","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-41008-7_8","article-title":"Immunotherapy for Neuro-Oncology.","volume-title":"Immunotherapy","author":"Majd","year":"2020"},{"issue":"10","key":"2021031215311187000_CIT0095","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","article-title":"Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2015","journal-title":"Ann Oncol."},{"issue":"5","key":"2021031215311187000_CIT0096","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"2021031215311187000_CIT0097","doi-asserted-by":"crossref","first-page":"2065-2065","DOI":"10.1200\/jco.2013.31.15_suppl.2065","article-title":"Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data","volume":"31","author":"Kleinberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021031215311187000_CIT0098","doi-asserted-by":"crossref","first-page":"vi21-vi22","DOI":"10.1093\/neuonc\/noz175.081","article-title":"ACTR-39. Pamiparib in combination with radiation therapy (RT) and\/or temozolomide (TMZ) in patients with newly diagnosed or recurrent\/refractory (R\/R) glioblastoma (GBM); phase 1b\/2 study update","volume":"21","author":"Piotrowski","year":"2019","journal-title":"Neuro Oncol"},{"key":"2021031215311187000_CIT0099","doi-asserted-by":"crossref","first-page":"vi17","DOI":"10.1093\/neuonc\/noy148.063","article-title":"ACTR-30. Phase 1B\/2 study to assess the clinical effects of pamiparib (BGB-290) in combination with radiation therapy (RT) and\/or temozolomide (TMZ) in patients with newly diagnosed or recurrent\/refractory glioblastoma (GBM)","volume":"20","author":"Shih","year":"2018","journal-title":"Neuro Oncol"},{"key":"2021031215311187000_CIT0100","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctro.2017.11.003","article-title":"PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status","volume":"8","author":"Fulton","year":"2018","journal-title":"Clin Transl Radiat Oncol."},{"issue":"7","key":"2021031215311187000_CIT0101","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann Oncol."},{"issue":"4","key":"2021031215311187000_CIT0102","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.celrep.2018.03.105","article-title":"Glioblastoma model using human cerebral organoids","volume":"23","author":"Ogawa","year":"2018","journal-title":"Cell Rep."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdab015\/36194990\/vdab015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab015\/36584826\/vdab015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/3\/1\/vdab015\/36584826\/vdab015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T15:34:34Z","timestamp":1615563274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdab015\/6128603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdab015","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]},"article-number":"vdab015"}}